Peer-Reviewed Study Shows Positive Impact of Nerivio’s® Guided Imagery, Education and Relaxation (GIER) Feature on Migraine Treatment Response

NETANYA, Israel and MONTCLAIR, N.J., Feb. 16, 2022 /PRNewswire/ — Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the publication of a new peer-reviewed study published in Pain Medicine, examining the use of combining Nerivio’s® Guided Imagery, Education and Relaxation (GIER) in-app optional behavioral intervention feature for acute treatment of migraine.

The GIER feature is an audio-visual software module of guided imagery, relaxation and education, designed for optional use in conjunction with the REN treatments. The 25-minute video, played on the user’s smartphone during the REN treatment, comprises three relaxation techniques: diaphragmatic breathing, progressive muscle relaxation, and guided imagery, as well as pain education content on migraine biology and the REN treatments. Patients may watch and/or listen to the video when Nerivio is activated for an acute treatment.

The study examined two matched cohorts of migraine patients. One group used Nerivio, a wearable migraine therapeutic, by itself. The other Nerivio+GIER group supplemented Nerivio treatments with the new GIER feature. Results from the match-controlled, dual-arm study indicate the Nerivio+GIER group had a higher proportion of patients achieving consistent pain relief, consistent improvement in functioning, and consistent return to normal functioning, beyond that of Nerivio treatment alone.

“It is well established that behavioral interventions such as diaphragmatic breathing, guided imagery and relaxation practices have preventive benefits for people living with migraine,” said Dr. Dawn Buse, Clinical Professor of Neurology at Albert Einstein College of Medicine and the first author of the study. “This study helped confirm our hypothesis that these interventions can help during a migraine attack as well. Migraine attacks are typically associated with physical pain and additional debilitating symptoms. Not surprisingly, this combination of symptoms tends to be accompanied by emotional and physical anxiety and distress. The natural protective “fight or flight” reaction of the nervous system, while well intentioned, is actually counterproductive during a migraine attack. Relaxation activities can provide comfort as well as help reduce muscle tension, encourage circulation, and generally moving the body and mind into a more comfortable and relaxed state. Our research demonstrates how expanding the patient’s toolbox with features such as GIER, incorporated into the Nerivio app, can be utilized to enhance the therapeutic benefits of neurostimulation by calming the nervous system while at the same time addressing the patient’s wellbeing.”

Prospective data from 170 patients, mostly chronic migraine patients (or people with 15 or more days with migraines per month), were analyzed (85 per group). 79% of the users in the Nerivio+GIER group experienced consistent pain relief (i.e., pain relief in at least 50% of the treatments), whereas 57% experienced it in the REN-only group. 71% of the users in the Nerivio+GIER group experienced consistent improvement of function (i.e., improvement of function in at least 50% of the treatments), compared to 57% in the REN-only group. 37.5% of the users in the Nerivio+GIER group experienced consistent complete return to full functioning (i.e., in at least 50% of the treatments), compared to 17.5% in the REN-only group. These differences between the groups were statistically significant.

“Our clinical development team at Theranica is dedicated to constantly improving patients’ benefit from Nerivio, and the optional GIER feature is part of that effort,” said Liron Rabani, a neuroscience Ph.D. and Theranica’s Chief Scientist, who co-authored the study. “While REN was proven effective on its own in fighting migraine symptoms, we thought that helping patients relax and enhance wellbeing during a migraine may have an additional therapeutic effect. We are glad to have this study demonstrate the usefulness of biobehavioral-mental-emotional enhancement in relieving pain and helping patients to return to function.”

Nerivio is a prescribed therapeutic wearable that deploys Remote Electrical Neuromodulation (REN) to activate the body’s native Conditioned Pain Modulation mechanism to treat pain and other symptoms associated with migraine. It is worn on the upper arm and controlled through an app on a patient’s smartphone, that also serves as a migraine diary. 

About Theranica

Theranica is a prescribed digital therapeutics company dedicated to creating effective, safe, affordable, low-side effect therapies for idiopathic pain conditions. The company’s award-winning flagship product, Nerivio^®, is the first FDA-cleared smartphone-controlled prescribed wearable device for acute treatment of migraine, and already serves over 25,000 people with migraine in the USA, including adolescents and veterans. Theranica is expanding its proprietary technology to develop solutions for additional idiopathic pain conditions. Nerivio has received FDA authorization and CE mark for use in acute treatment of episodic and chronic migraine in adult and adolescent patients.

Learn more by visiting our websites, theranica.com, nerivio.com and following us on LinkedIn, Twitter, Instagram and Facebook.

Media Contact
Nechama Feuerstein
FINN Partners
Nechama.Feuerstein@finnpartners.com
+1-929-222-8006

Theranica Contact
Ronen Jashek
ronenj@theranica.com 
+972-72-390-9750

View original content:https://www.prnewswire.com/news-releases/peer-reviewed-study-shows-positive-impact-of-nerivios-guided-imagery-education-and-relaxation-gier-feature-on-migraine-treatment-response-301483460.html

SOURCE Theranica